| Protein Name: | Dihydropyrimidine dehydrogenase (Q12882) |
|---|---|
| Gene Name: | DPYD |
| Description: | Dihydropyrimidine dehydrogenase [NADP+] precursor (EC 1 3 1 2) (DPD) (DHPDHase) (Dihydrouracil dehydrogenase) (Dihydrothymine dehydrogenase) |
| PDB ID: | |
| Protein Family: | |
| Protein Category: | Enzyme |
This panel provides drug-protein interaction and their ADRs along with references
| Interacting Drugs | Toxicity | Mechanism | Reference |
|---|---|---|---|
| Flucytosine | 5-Fluorouracil-Associated Toxicity | Severe 5-fluorouracil-associated toxicity (including death) [ ADR Type 2 ] | Population characteristics of hepatic dihydropyrimidine dehydrogenase activity, a key metabolic enzyme in 5-fluorouracil chemotherapy |
| Flucytosine | Angina Pectoris | It is recommended to measure DPD activity prior to 5-FU based chemotherapy@ which might be helpful in avoiding drug-related toxicity by adjusting the dose of 5-FU individually [ ADR Type 1 ] | Putative role of dihydropyrimidine dehydrogenase in the toxic side effect of 5-fluorouracil in colorectal cancer patients |
| Flucytosine | Coma | Cancer patients with DPD deficiency are at increased risk for developing severe neurological toxicity secondary to 5-FU chemotherapy@ and that infusional thymidine should be considered as a potential rescue agent against this particular host toxicity. [ ADR Type 2 ] | Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency |
| Flucytosine | Encephalopathy | Cancer patients with DPD deficiency are at increased risk for developing severe neurological toxicity secondary to 5-FU chemotherapy@ and that infusional thymidine should be considered as a potential rescue agent against this particular host toxicity. [ ADR Type 2 ] | Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency |
| Flucytosine | Gastrointestinal Toxicity | Severe and potentially life-threatening gastrointestinal toxicity@ myelosuppression@ and neurological toxicity [ ADR Type 2 ] | Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency |
| Flucytosine | Hypertension | It is recommended to measure DPD activity prior to 5-FU based chemotherapy@ which might be helpful in avoiding drug-related toxicity by adjusting the dose of 5-FU individually [ ADR Type 1 ] | Putative role of dihydropyrimidine dehydrogenase in the toxic side effect of 5-fluorouracil in colorectal cancer patients |
| Flucytosine | Myelosuppression | Severe and potentially life-threatening gastrointestinal toxicity@ myelosuppression@ and neurological toxicity [ ADR Type 2 ] | Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency |
| Flucytosine | Neurological Toxicity | Severe and potentially life-threatening gastrointestinal toxicity@ myelosuppression@ and neurological toxicity [ ADR Type 2 ] | Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency |
| Fluorouracil | Anemia | Eniluracil inactivates dihydropyrimidine dehydrogenase activity@bone marrow suppression is the primary and dose-limiting toxicity of this regimen@other toxicities included diarrhea@ mucositis@ anemia@ anorexia@ nausea@ vomiting@ and fatigue [ ADR Type 4 ] | Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer |
| Fluorouracil | Anorexia | Eniluracil inactivates dihydropyrimidine dehydrogenase activity@bone marrow suppression is the primary and dose-limiting toxicity of this regimen@other toxicities included diarrhea@ mucositis@ anemia@ anorexia@ nausea@ vomiting@ and fatigue [ ADR Type 4 ] | Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer |
| Fluorouracil | Attenuation Of The Antitumor Activity | (R)-5-fluoro-5@6-dihydrouracil inactivates dihydropyrimidine dehydrogenase activity@which may lead to attenuation of the antitumor activity of 5-fluorouracil [ ADR Type 4 ] | Attenuation of the antitumor activity of 5-fluorouracil by (R)-5-fluoro-5,6-dihydrouracil |
| Fluorouracil | Bone Marrow Suppression | Eniluracil inactivates dihydropyrimidine dehydrogenase activity@bone marrow suppression is the primary and dose-limiting toxicity of this regimen@other toxicities included diarrhea@ mucositis@ anemia@ anorexia@ nausea@ vomiting@ and fatigue [ ADR Type 4 ] | Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer |
| Fluorouracil | Diarrhoea | Eniluracil inactivates dihydropyrimidine dehydrogenase activity@bone marrow suppression is the primary and dose-limiting toxicity of this regimen@other toxicities included diarrhea@ mucositis@ anemia@ anorexia@ nausea@ vomiting@ and fatigue [ ADR Type 4 ] | Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer |
| Fluorouracil | Fatigue | Eniluracil inactivates dihydropyrimidine dehydrogenase activity@bone marrow suppression is the primary and dose-limiting toxicity of this regimen@other toxicities included diarrhea@ mucositis@ anemia@ anorexia@ nausea@ vomiting@ and fatigue [ ADR Type 4 ] | Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer |
| Fluorouracil | Mucositis | Eniluracil inactivates dihydropyrimidine dehydrogenase activity@bone marrow suppression is the primary and dose-limiting toxicity of this regimen@other toxicities included diarrhea@ mucositis@ anemia@ anorexia@ nausea@ vomiting@ and fatigue [ ADR Type 4 ] | Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer |
| Fluorouracil | Myelotoxicity | myelotoxicity [ ADR Type 1 ] | Pharmacogenetics in cancer chemotherapy: balancing toxicity and response |
| Fluorouracil | Neurotoxicity | Neurotoxicity [ ADR Type 1 ] | Pharmacogenetics in cancer chemotherapy: balancing toxicity and response |
| Fluorouracil | Toxicity Of Fura Chemotherapy | Decreased DPD protein in the liver cytosol from DPD-deficient patients compared to normal subjects may be useful in improving the effectiveness and/or lessening the toxicity of FUra chemotherapy. [ ADR Type 3 ] | Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy |
| Fluorouracil | Vomiting | Eniluracil inactivates dihydropyrimidine dehydrogenase activity@bone marrow suppression is the primary and dose-limiting toxicity of this regimen@other toxicities included diarrhea@ mucositis@ anemia@ anorexia@ nausea@ vomiting@ and fatigue [ ADR Type 4 ] | Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer |
This panel provides information on drug category
| Toxicity | Source |
|---|